SI113, a specific inhibitor of the Sgk1 kinase activity that counteracts cancer cell proliferation

Cellular Physiology and Biochemistry

Volumn 35, Issue 5, 2015, Pages 2006-2018

  D'Antona, Lucia ^a   Amato, Rosario ^a   Talarico, Cristina ^a   Ortuso, Francesco ^a   Menniti, Miranda ^a   Dattilo, Vincenzo ^a   Iuliano, Rodolfo ^a   Gigliotti, Francesco ^a   Artese, Anna ^a   Costa, Giosuè ^a   Schenone, Silvia ^b   Musumeci, Francesca ^b   Abbruzzese, Claudia ^d   Botta, Lorenzo ^c   Trapasso, Francesco ^a   Alcaro, Stefano ^a   Paggi, Marco G ^d   Perrotti, Nicola ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

^d REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Apoptosis; Cancer; Kinase inhibitor; Necrosis; SGK1; Small molecule

Indexed keywords

4 IODO 2,5 DIMETHOXYAMPHETAMINE; PACLITAXEL; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN MDM2; PROTEIN P53; SERUM AND GLUCOCORTICOID REGULATED KINASE 1; SI 113; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; IMMEDIATE EARLY PROTEIN; INSULIN; MDM2 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; SERUM-GLUCOCORTICOID REGULATED KINASE; SI113 COMPOUND;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER MODEL; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CHEMOSENSITIVITY; COLON CARCINOMA; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; NECROSIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; SUBSTITUTION REACTION; ANTAGONISTS AND INHIBITORS; CHEMISTRY; COLONIC NEOPLASMS; DRUG EFFECTS; G1 PHASE CELL CYCLE CHECKPOINT; MCF 7 CELL LINE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

MURINAE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; IMMEDIATE-EARLY PROTEINS; INSULIN; MCF-7 CELLS; NECROSIS; PACLITAXEL; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN STABILITY; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-MDM2; PYRAZOLES; PYRIMIDINES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84927945625     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000374008     Document Type: Article

References (39)

1. Bruhn MA, Pearson RB, Hannan RD, Sheppard KE: Second AKT: the rise of SGK in cancer signalling. Growth Factors 2010;28:394-408.
2. Lang F, Cohen P: Regulation and physiological roles of serum-and glucocorticoid-induced protein kinase isoforms. Sci STKE 2001;2001:re17.
3. Perrotti N, He RA, Phillips SA, Haft CR, Taylor SI: Activation of serum-and glucocorticoid-induced protein kinase (Sgk) by cyclic AMP and insulin. J Biol Chem 2001;276:9406-9412.
4. Faletti CJ, Perrotti N, Taylor SI, Blazer-Yost BL: sgk: an essential convergence point for peptide and steroid hormone regulation of ENaC-mediated Na+ transport. Am J Physiol Cell Physiol 2002;282:C494-C500.
5. Hong F, Larrea MD, Doughty C, Kwiatkowski DJ, Squillace R, Slingerland JM: mTOR-raptor binds and activates SGK1 to regulate p27 phosphorylation. Mol Cell 2008;30:701-711.
6. Francipane MG, Lagasse E: Selective targeting of human colon cancer stem-like cells by the mTOR inhibitor Torin-1. Oncotarget 2013;4:1948-1962.
7. Leong ML, Maiyar AC, Kim B, O'Keeffe BA, Firestone GL: Expression of the serum-and glucocorticoidinducible protein kinase, Sgk, is a cell survival response to multiple types of environmental stress stimuli in mammary epithelial cells. J Biol Chem 2003;278:5871-5882.
8. Mikosz CA, Brickley DR, Sharkey MS, Moran TW, Conzen SD: Glucocorticoid receptor-mediated protection from apoptosis is associated with induction of the serine/threonine survival kinase gene, sgk-1. J Biol Chem 2001;276:16649-16654.
9. Wu W, Chaudhuri S, Brickley DR, Pang D, Karrison T, Conzen SD: Microarray analysis reveals glucocorticoidregulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells. Cancer Res 2004;64:1757-1764.
10. Chung EJ, Sung YK, Farooq M, Kim Y, Im S, Tak WY, Hwang YJ, Kim YI, Han HS, Kim JC, Kim MK: Gene expression profile analysis in human hepatocellular carcinoma by cDNA microarray. Mol Cells 2002;14:382-387.
11. Amato R, Menniti M, Agosti V, Boito R, Costa N, Bond HM, Barbieri V, Tagliaferri P, Venuta S, Perrotti N: IL-2 signals through Sgk1 and inhibits proliferation and apoptosis in kidney cancer cells. J Mol Med 2007;85:707-721.
12. Sherk AB, Frigo DE, Schnackenberg CG, Bray JD, Laping NJ, Trizna W, Hammond M, Patterson JR, Thompson SK, Kazmin D, Norris JD, McDonnell DP: Development of a small-molecule serum-and glucocorticoidregulated kinase-1 antagonist and its evaluation as a prostate cancer therapeutic. Cancer Res 2008;68:7475-7483.
13. Abbruzzese C, Mattarocci S, Pizzuti L, Mileo AM, Visca P, Antoniani B, Alessandrini G, Facciolo F, Amato R, D'Antona L, Rinaldi M, Felsani A, Perrotti N, Paggi MG: Determination of SGK1 mRNA in non-small cell lung cancer samples underlines high expression in squamous cell carcinomas. J Exp Clin Cancer Res 2012;31:4.
14. Nasir O, Wang K, Foller M, Gu S, Bhandaru M, Ackermann TF, Boini KM, Mack A, Klingel K, Amato R, Perrotti N, Kuhl D, Behrens J, Stournaras C, Lang F: Relative resistance of SGK1 knockout mice against chemical carcinogenesis. IUBMB Life 2009;61:768-776.
15. Amato R, D'Antona L, Porciatti G, Agosti V, Menniti M, Rinaldo C, Costa N, Bellacchio E, Mattarocci S, Fuiano G, Soddu S, Paggi MG, Lang F, Perrotti N: Sgk1 activates MDM2-dependent p53 degradation and affects cell proliferation, survival, and differentiation. J Mol Med 2009;87:1221-1239.
16. Amato R, Scumaci D, D'Antona L, Iuliano R, Menniti M, Di SM, Faniello MC, Colao E, Malatesta P, Zingone A, Agosti V, Costanzo FS, Mileo AM, Paggi MG, Lang F, Cuda G, Lavia P, Perrotti N: Sgk1 enhances RANBP1 transcript levels and decreases taxol sensitivity in RKO colon carcinoma cells. Oncogene 2013;32:4572-4578.
17. Menniti M, Iuliano R, Foller M, Sopjani M, Alesutan I, Mariggio S, Nofziger C, Perri AM, Amato R, Blazer-Yost B, Corda D, Lang F, Perrotti N: 60kDa lysophospholipase, a new Sgk1 molecular partner involved in the regulation of ENaC. Cell Physiol Biochem 2010;26:587-596.
18. Menniti M, Iuliano R, Amato R, Boito R, Corea M, Le PI, Gulletta E, Fuiano G, Perrotti N: Serum and glucocorticoid-regulated kinase Sgk1 inhibits insulin-dependent activation of phosphomannomutase 2 in transfected COS-7 cells. Am J Physiol Cell Physiol 2005;288:C148-C155.
19. Christiansen MN, Chik J, Lee L, Anugraham M, Abrahams JL, Packer NH: Cell surface protein glycosylation in cancer. Proteomics 2014;14:525-546.
20. Holst S, Stavenhagen K, Balog CI, Koeleman CA, McDonnell LM, Mayboroda OA, Verhoeven A, Mesker WE, Tollenaar RA, Deelder AM, Wuhrer M: Investigations on aberrant glycosylation of glycosphingolipids in colorectal cancer tissues using liquid chromatography and matrix-assisted laser desorption time-of-flight mass spectrometry (MALDI-TOF-MS). Mol Cell Proteomics 2013;12:3081-3093.
21. Leve F, Marcondes TG, Bastos LG, Rabello SV, Tanaka MN, Morgado-Diaz JA: Lysophosphatidic acid induces a migratory phenotype through a crosstalk between RhoA-Rock and Src-FAK signalling in colon cancer cells. Eur J Pharmacol 2011;671:7-17.
22. Zhang H, Bialkowska A, Rusovici R, Chanchevalap S, Shim H, Katz JP, Yang VW, Yun CC: Lysophosphatidic acid facilitates proliferation of colon cancer cells via induction of Kruppel-like factor 5. J Biol Chem 2007;282:15541-15549.
23. Lang F, Perrotti N, Stournaras C: Colorectal carcinoma cells-regulation of survival and growth by SGK1. Int J Biochem Cell Biol 2010;42:1571-1575.
24. Lang F, Voelkl J: Therapeutic potential of serum and glucocorticoid inducible kinase inhibition. Expert Opin Investig Drugs 2013;22:701-714.
25. Towhid ST, Liu GL, Ackermann TF, Beier N, Scholz W, Fuchss T, Toulany M, Rodemann HP, Lang F: Inhibition of colonic tumor growth by the selective SGK inhibitor EMD638683. Cell Physiol Biochem 2013;32:838-848.
26. Bruhn MA, Pearson RB, Hannan RD, Sheppard KE: AKT-independent PI3-K signaling in cancer -emerging role for SGK3. Cancer Manag Res 2013;5:281-292.
27. Skor MN, Wonder EL, Kocherginsky M, Goyal A, Hall BA, Cai Y, Conzen SD: Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer. Clin Cancer Res 2013;19:6163-6172.
28. Angelucci A, Schenone S, Gravina GL, Muzi P, Festuccia C, Vicentini C, Botta M, Bologna M: Pyrazolo[3,4-d] pyrimidines c-Src inhibitors reduce epidermal growth factor-induced migration in prostate cancer cells. Eur J Cancer 2006;42:2838-2845.
29. Radi M, Dreassi E, Brullo C, Crespan E, Tintori C, Bernardo V, Valoti M, Zamperini C, Daigl H, Musumeci F, Carraro F, Naldini A, Filippi I, Maga G, Schenone S, Botta M: Design, synthesis, biological activity, and ADME properties of pyrazolo[3,4-d]pyrimidines active in hypoxic human leukemia cells: a lead optimization study. J Med Chem 2011;54:2610-2626.
30. Ortuso F, Amato R, Artese A, D'Antona L, Costa G, Talarico C, Gigliotti F, Bianco C, Trapasso F, Schenone S, Musumeci F, Botta L, Perrotti N, Alcaro S: In Silico Identification and Biological Evaluation of Novel Selective Serum/Glucocorticoid-Inducible Kinase 1 Inhibitors Based on the Pyrazolo-Pyrimidine Scaffold. J Chem Inf Model 2014.
31. Perrotti N, Taylor SI, Richert ND, Rapp UR, Pastan IH, Roth J: Immunoprecipitation of insulin receptors from cultured human lymphocytes (IM-9 cells) by antibodies to pp60src. Science 1985;227:761-763.
32. Perrotti N, Grunberger G, Richert ND, Taylor SI: Immunological similarity between the insulin receptor and the protein encoded by the src oncogene. Endocrinology 1986;118:2349-2354.
33. Bardou M, Barkun AN, Martel M: Obesity and colorectal cancer. Gut 2013;62:933-947.
34. Nagata N, Sakamoto K, Arai T, Niikura R, Shimbo T, Shinozaki M, Aoki T, Kishida Y, Sekine K, Tanaka S, Okubo H, Watanabe K, Sakurai T, Yokoi C, Akiyama J, Yanase M, Noda M, Itoh T, Mizokami M, Uemura N: Visceral abdominal fat measured by computed tomography is associated with an increased risk of colorectal adenoma. Int J Cancer 2014.
35. Abbruzzese C, Diodoro MG, Sperduti I, Mileo AM, Pattaro G, De SL, Cosimelli M, Perrotti N, Paggi MG: Detection of phosphorylated insulin receptor in colorectal adenoma and adenocarcinoma: implications for prognosis and clinical outcome. J Cell Physiol 2015;230:562-567.
36. Capra M, Nuciforo PG, Confalonieri S, Quarto M, Bianchi M, Nebuloni M, Boldorini R, Pallotti F, Viale G, Gishizky MI, Draetta GF, Di Fiore PP: Frequent alterations in the expression of Serine/Threonine kinases in Human Cancers . Cancer Res 2006;66:8: 147-8154.
37. Yap TA, Yan L, Patnaik A, Fearen I, Olmos D, Papadopoulos K, Baird RD, Delgado L, Taylor A, Lupinacci L, Riisnaes R, Pope LL, Heaton SP, Thomas G, Garrett MD, Sullivan DM, de Bono JS, Tolcher AW: First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol 2011;29:4688-4695.
38. Konopleva MY, Walter RB, Faderl SH, Jabbour EJ, Zeng Z, Borthakur G, Huang X, Kadia TM, Ruvolo PP, Feliu JB, Lu H, Debose L, Burger JA, Andreeff M, Liu W, Baggerly KA, Kornblau SM, Doyle LA , Estey EH, Kantarjian HM: Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia. Clin Cancer Res 2014;20:2226-2235
39. Manetti F, Santucci A, Locatelli GA, Maga G, Spreafico A, Serchi T, Orlandini M, Bernardini G, Caradonna NP, Spallarossa A, Brullo C, Schenone S, Bruno O, Ranise A, Bondavalli F, Hoffmann O, Bologna M, Angelucci A, Botta M: Identification of a novel pyrazolo[3,4-d]pyrimidine able to inhibit cell proliferation of a human osteogenic sarcoma in vitro and in a xenograft model in mice. J Med Chem 2007;50:5579-5588.